NKTR लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...

Stats
आज की मात्रा	558 779
औसत मात्रा	2.52M
बाजार मूल्य	242.38M
EPS	$0 ( 2024-03-04 )
अगली कमाई की तारीख	( $-0.200 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.910
ATR14	$0.00300 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Deep Track Capital, Lp	Buy	0	Common Stock
2024-02-20	Zalevsky Jonathan	Sell	9 014	Common Stock
2024-02-20	Wilson Mark Andrew	Sell	7 606	Common Stock
2024-02-20	Robin Howard W	Sell	20 033	Common Stock
2023-12-13	Zalevsky Jonathan	Buy	250 000	Stock Option

INSIDER POWER
84.96
Last 97 transactions
Buy: 6 976 063 \| Sell: 637 451

मात्रा सहसंबंध

लंबा: 0.50 (weak)

छोटा: 0.86 (strong)

Signal:(65.532) Same movement expected

Nektar Therapeutics सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Nektar Therapeutics सहसंबंध - मुद्रा/वस्त्र

0.00
( neutral )

-0.09
( neutral )

Nektar Therapeutics वित्तीय

Annual	2023
राजस्व:	$90.12M
सकल लाभ:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2023
राजस्व:	$90.12M
सकल लाभ:	$53.48M (59.34 %)
EPS:	$-1.450

FY	2022
राजस्व:	$92.06M
सकल लाभ:	$70.42M (76.50 %)
EPS:	$-1.970

FY	2021
राजस्व:	$101.91M
सकल लाभ:	$77.01M (75.57 %)
EPS:	$-2.86

Financial Reports:

No articles found.

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.